DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 129 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q3 2023. The put-call ratio across all filers is 2.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $640,396 | -12.5% | 52,192 | -14.9% | 0.00% | 0.0% |
| Q2 2023 | $732,053 | +431.9% | 61,311 | +495.6% | 0.00% | – |
| Q1 2023 | $137,631 | -42.1% | 10,294 | -6.9% | 0.00% | – |
| Q4 2022 | $237,882 | +8.6% | 11,054 | +1.1% | 0.00% | – |
| Q3 2022 | $219,000 | +22.3% | 10,929 | +9.5% | 0.00% | – |
| Q2 2022 | $179,000 | +86.5% | 9,985 | +3.1% | 0.00% | – |
| Q1 2022 | $96,000 | -6.8% | 9,687 | +58.6% | 0.00% | – |
| Q4 2021 | $103,000 | -27.0% | 6,106 | +2.5% | 0.00% | – |
| Q3 2021 | $141,000 | – | 5,957 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 2,548,403 | $54,841,633 | 43.06% |
| PATHWAY CAPITAL MANAGEMENT, LP | 995,686 | $21,427,163 | 38.24% |
| Atlas Venture Life Science Advisors, LLC | 7,568,317 | $162,870,182 | 19.62% |
| RA Capital Management | 7,040,622 | $151,514,185 | 3.07% |
| COMMODORE CAPITAL LP | 739,661 | $15,918 | 2.40% |
| GREAT POINT PARTNERS LLC | 544,451 | $11,716,586 | 2.30% |
| Nicholas Investment Partners, LP | 786,554 | $16,926,642 | 1.48% |
| Boxer Capital, LLC | 1,189,943 | $25,607,573 | 1.35% |
| Parkman Healthcare Partners LLC | 224,483 | $4,830,874 | 1.29% |
| Cheyne Capital Management (UK) LLP | 27,223 | $585,839 | 1.02% |